TIRZEPATIDE

Is a dual GLP-1 and GIP agonist commercially known as Mounjaro and Zepbound. It suppresses appetite, improves insulin sensitivity, and delivers clinically proven fat loss superior to Semaglutide. It is administered once weekly for consistent, progressive results. One of the most effective and well-studied metabolic peptides available.